TradersLink
$NNOXAug 18, 2026, 8:10 AM ETAI processed

Nanox (NNOX) signs exclusive UK reseller deal with Vertec for HealthOST AI bone solution

AI Summary

Nanox AI signed an exclusive three-year sales reseller agreement with Vertec Scientific to commercialize its HealthOST AI bone solution in the United Kingdom, subject to Vertec meeting minimum annual license commitments. HealthOST is FDA‐cleared and UKCA/CE‐marked to analyze routine CT scans opportunistically for vertebral fragility/osteoporosis (no extra imaging required); NICE recommended the technology for NHS use in Nov 2025, and Vertec’s established DXA/bone-health footprint should aid rollout.

Positives

  • Exclusive three-year UK reseller license with Vertec expands commercial reach into NHS and private UK sites
  • HealthOST is FDA‑cleared and UKCA/CE‑marked and analyzes routine CT scans opportunistically (no additional imaging or radiation)
  • NICE recommended HealthOST for NHS use in Nov 2025, supporting potential adoption

Negatives

  • Commercialization is conditional on Vertec meeting minimum annual license commitments
  • Initial agreement term is three years — short window to prove commercial traction
  • Company discloses historical recurring losses and liquidity/going-concern risks that could affect execution